Drug intelligence / Profile preview

F16-IL2 + paclitaxel

Development stage: Unknown
Lead developer: Philogen
Modality: Nucleic Acid-Directed Small Molecules → Small Molecules, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Covalent Small Molecules → Small Molecules, Cytokines & Interferons → Recombinant Proteins and Enzymes, Classical Binding Small Molecules → Small Molecules
Administration: Intravenous

Overview

F16-IL2 + paclitaxel is a combination therapy under clinical investigation for the treatment of advanced solid tumors. F16-IL2 is a recombinant antibody-cytokine fusion protein composed of the antibody fragment F16 (which targets the A1 domain of tenascin-C in tumor stroma) and human interleukin-2 (IL-2). This immunocytokine selectively localizes to tumor tissue and enhances immune-mediated anti-tumor activity. Paclitaxel is a well-established chemotherapeutic agent that inhibits cancer cell division by stabilizing microtubules, thereby blocking mitosis. The combination aims to leverage both direct cytotoxic effects from paclitaxel and immune activation from targeted IL-2 delivery via F16. Clinical studies have shown this regimen can be safely administered with manageable toxicity profiles in patients with progressive solid tumors[4][3][5]. Paclitaxel is marketed under brand names such as Taxol and Onxol.

Brand names: TaxolOnxol
Other names: F16IL2 and paclitaxelF-16IL2 and paclitaxelF 16IL2 and paclitaxelTeleukin + paclitaxel

Targets

TNC-A1 (Tenascin-C fibronectin type III-A1 domain)IL-2R (Interleukin-2/interleukin-15 receptor complex)TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on F16-IL2 + paclitaxel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on F16-IL2 + paclitaxel.

Explore the full profile